Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Clovis Posts Data on Rubraca Study for Pancreatic Cancer
by Zacks Equity Research
Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.
Advaxis Up on Positive Early-Stage Immunotherapy Study Data
by Zacks Equity Research
Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
Implied Volatility Surging for Clovis (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.
Why Is Clovis (CLVS) Down 21% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover
by Zacks Equity Research
Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.
AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe
by Zacks Equity Research
Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
Immunomedics Gets CRL From FDA for Breast Cancer Candidate
by Zacks Equity Research
Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Immunomedics Enters Into Supply Deal for Breast Cancer Drug
by Zacks Equity Research
Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.
AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.
Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Clovis (SFIX) stock based on the movements in the options market lately.
Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Clovis Oncology (CLVS) shares rose nearly 7% in the last trading session, amid huge volumes.
Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%
by Zacks Equity Research
Glaxo (GSK) announces definitive deal to buy TESARO.
TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer
by Zacks Equity Research
TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.
Clovis (CLVS) Up 45.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up
by Zacks Equity Research
Clovis Oncology's (CLVS) shares rise more than 5% following the issuance of a new patent for Rubraca in the United States for claims related to methods of treating cancer with its high dosage strength.
TESARO Shares Rally on Rumors of Potential Acquisition Offer
by Zacks Equity Research
Per a Bloomberg report, TESARO (TSRO) may have received an acquisition offer. Shares rally on rumors.
Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
by Zacks Equity Research
PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.
AstraZeneca's Lynparza Gets Priority Review in 1st Line Use
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.